Vancouver, BC, May 13, 2025 ( GLOBE NEWSWIRE ) -- American Tungsten Corp. ( CSE:TUNG ) ( OTCQB:DEMRF ) ( FSE:RK9 ) ( "American Tungsten" or the "Company" ) announces that the Company's CEO, Ali Haji will host a webinar to give an overview of the company's recent developments.

Company to host a webcast today at 8:30 a.m. Eastern Time ...

- ATTRibute-CM, BridgeBio's Phase 3 clinical trial of acoramidis in patients with ATTR-CM, achieved statistical significance in reducing the risk of ACM or first CVH versus placebo in ATTRv-CM patients ( 59.1% risk reduction ) , establishing the mechanistic hypothesis that stabilizing TTR may ...

MONTREAL, May 13, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc. ( TSX: GUD ) ( "Knight" ) , a pan-American ( ex-US ) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2025 RBC ...

MONTREAL, May 13, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc. ( TSX: GUD ) ( "Knight" ) , a pan-American ( ex-US ) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 2025 RBC ...

YAVNE, Israel, May 13, 2025 ( GLOBE NEWSWIRE ) -- MediWound Ltd. MDWD, a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds.

HOUSTON, May 13, 2025 ( GLOBE NEWSWIRE ) -- Intuitive Machines, Inc. ( Nasdaq: LUNR, "Intuitive Machines," or the "Company" ) , a leading space technology and infrastructure services company, today announced its financial results for the first quarter ended March 31, 2025.

Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy

RESTON, Va., May 13, 2025 /PRNewswire/ -- V2X Inc. VVX has been selected as an awardee on the U.S. Army's Live Training, Ranges, and Combat Training Centers ( LTRaC ) Indefinite Delivery, Indefinite Quantity ( IDIQ ) Multiple Award Contract 3. This strategic contract, supporting the U.S.

First of five Phase 2 trials for AL001 begins in healthy subjects with topline data expected by end of 2025. Preclinical data showed AL001 improved brain absorption with lower blood lithium levels compared to current treatments.